Lupeol, an Androgen Receptor Inhibitor, Enhances the Chemosensitivity of Prostate Cancer Stem Cells to Antiandrogen Enzalutamide-Based Therapy

Researchers explored Lupeol’s potential in enhancing the chemosensitivity of chemoresistant prostate cancer cells to Enzalutamide in vitro and in a mouse model.